ISSN: 1522-8517

Journal Home

Journal Guideline

Neuro-Oncology Q1 Unclaimed

Oxford University Press United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Neuro-Oncology is a journal indexed in SJR in Oncology and Cancer Research with an H index of 150. It has an SJR impact factor of 4,833 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 4,833.

Neuro-Oncology focuses its scope in these topics and keywords: glioblastoma, glioma, tumor, cell, brain, central, diagnosis, therapeutic, disease, cells, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q1) Neurology (clinical) (Q1) Oncology (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

3465 €

Non OA

Metrics

4,833

SJR Impact factor

150

H Index

254

Total Docs (Last Year)

715

Total Docs (3 years)

5645

Total Refs

6916

Total Cites (3 years)

451

Citable Docs (3 years)

9.53

Cites/Doc (2 years)

22.22

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

CA - A Cancer Journal for Clinicians Q1
Molecular Cancer Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1

Compare this journals

Aims and Scope

Best articles by citations

Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma

Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab

Response and progression in recurrent malignant glioma

Consensus Conference on Cancer Registration of Brain and Central Nervous

Editorial

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

DRES-07. SIGNIFICANT SEX DIFFERENCES IN TEMOZOLOMIDE EFFICACY IN GLIOBLASTOMA (GBM) ARE DETECTABLE IN CELL AND PATIENT BASED EVALUATIONS

Medical management of brain tumors and the sequelae of treatment

Incidence of brain metastasis at initial presentation of lung cancer

Biology and management of ependymomas

CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2

SHOW MORE ARTICLES

Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life

Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models

Surgery for primary supratentorial brain tumors in the United States,

Immunohistochemical staining for ganglioside GD1b as a diagnostic and prognostic marker for primary human brain tumors

Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients

Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine

Penetration of intra-arterially administered vincristine in experimental

Atypical white matter volume development in children following

ATPS-74IS MORE CHEMOTHERAPY BETTER? PROLONGED SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA RECEIVING MORE THAN SIX CYCLES OF ADJUVANT TEMOZOLOMIDE

Posttransplant primary CNS lymphoma

Retraction notice: Diffuse midline glioma with H3 K27M mutation: a comparison integrating the clinical, radiological, and molecular features between adult and pediatric patients

AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor